Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Oncotelic Therapeutics, Inc.

OTC: OTLC · Life Sciences · 4 alerts · CIK 908259

Share price
$0.0134Close, Nov 16
Market cap
$6.13M
Shares outstanding
457.51MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oncotelic Therapeutics, Inc. filings on SEC EDGAR ↗

4:31 PM ET 10-Q
Financial Results

Oncotelic Therapeutics Q3 2026 Results: Net Loss of $1.11M, Loss Widens

Oncotelic Therapeutics reported a net loss of $2.92 million for the nine months ended September 30, 2026, compared to a loss of $1.07 million in the prior year period. The company's balance sheet is dominated by a $388 million investment in GMP Bio at fair value, while it continues to manage significant debt obligations and a working capital deficit.

Key figure
Net loss $1.11M
9:00 AM ET Form 4
Insider Buying

Oncotelic Therapeutics Chairman and CEO Vuong Trieu Buys $17.8K of Stock

Vuong Trieu, Chairman and CEO, bought 1,044,990 shares of Oncotelic Therapeutics, Inc. at $0.017 a share, worth $17.8K in total on Oct 29, 2026. Shares held after the trade: 95,481,309 (+1.1%).

Value
$17.8K
Shares
1,044,990
Price
$0.0170
Role
Chairman and CEO
Holding change
+1.1%
Trade date
Oct 29, 2026
9:00 AM ET 8-K
Investor Presentation

Oncotelic Therapeutics Investor Presentation

Oncotelic Therapeutics presented its Partitioned Literature Aggregation (PLA) framework at the 22nd Drug Discovery Strategic Summit. The presentation detailed the use of AI and literature analysis to identify a four-gene mTOR signature for hepatocellular carcinoma and outlined plans for an AI-driven research environment targeting 100 billion protein-related vectors.

9:01 AM ET 8-K
Investor Presentation

Oncotelic Therapeutics Investor Presentation

Oncotelic Therapeutics presented details on its PDAOAI platform and hepatocellular carcinoma (HCC) research at the Drug Discovery 2026 conference. The presentations highlighted a four-gene mTOR-related signature associated with patient survival and introduced the 'BIO REBOOT' initiative to support new therapeutic research projects.

Counterparty
Drug Discovery 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.